Lytix Biopharma Valuation
Is LYTIX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LYTIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LYTIX?
Key metric: As LYTIX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is LYTIX's PS Ratio? | |
|---|---|
| PS Ratio | 29.5x |
| Sales | NOK 10.76m |
| Market Cap | NOK 317.51m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 25.7x |
| Enterprise Value/EBITDA | -3.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LYTIX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.6x | ||
HBC Hofseth BioCare | 2.2x | n/a | NOK 534.4m |
AZT ArcticZymes Technologies | 6x | 14.2% | NOK 669.0m |
ABS Arctic Bioscience | 1.7x | 35.6% | NOK 52.8m |
PCIB PCI Biotech Holding | 8.7x | n/a | NOK 52.3m |
LYTIX Lytix Biopharma | 29.5x | 137.9% | NOK 317.5m |
Price-To-Sales vs Peers: LYTIX is expensive based on its Price-To-Sales Ratio (29.5x) compared to the peer average (4.6x).
Price to Sales Ratio vs Industry
How does LYTIX's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: LYTIX is expensive based on its Price-To-Sales Ratio (29.5x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is LYTIX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 29.5x |
| Fair PS Ratio | 333.3x |
Price-To-Sales vs Fair Ratio: LYTIX is good value based on its Price-To-Sales Ratio (29.5x) compared to the estimated Fair Price-To-Sales Ratio (333.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.